Akademik Veri Yönetim Sistemi
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.10, sa.1, ss.19-27, 2005 (ESCI)
Interferon-alpha (IFN-alpha) and lamivudine are the most effective agents used in the treatment of chronic hepatitis B virus (HBV) infection. The aim of this study was to compare the efficacy of combination therapy with lamivudine and IFN-a versus monotherapies (IFN-alpha and lamivudine) in patients with chronic HBV infection. Sixty-one patients were enrolled in this study. Thirty-four, 18 and 9 of the patients received combination therapy, IFN-alpha monotherapy and lamivudine monotherapy, respectively. Virologic response rates to IFN-alpha monotherapy, combination therapy and lamivudine monotherapy at the end of the treatments in these patients were 77.8%, 88.2% and 66.7%, respectively (p>0.05). The sustained response rates to the same therapy groups were 50%, 44.1% and 44.4%, respectively (p>0.05). The mean ALT value at the end of the treatments were found to have decreased in a statistically significant degree compared with the baseline levels in each group (IFN-alpha p=0.005, combination p<0.001 and lamivudine p=0.011). In the patients with nonmutant chronic HBV infection, the mean ALT values decreased in each group, but only in the combination therapy group, the mean ALT values at the baseline and at month 12 were significantly different between groups (p=0.001). Virologic response rates in the patients with precore mutant chronic HBV infection were 86.7% in the IFN- a monotherapy group, 84.2% in the combination therapy group and 100% in the lamivudine monotherapy group at the end of the treatments ( p> 0.05). We did not find any statistically significant difference between monotherapies and combination therapy groups related to sustained response in chronic HBV infection. It was found more effective the combination therapy in the patients with high pretreatment HBV- DNA levels, and the treatment regimens containing lamivudine in the patients with precore mutant chronic HBV infection.